Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9256
Name colorectal cancer
Definition A large intestine cancer that is located_in the colon and/or located_in the rectum.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 mutant PD0166285 colorectal cancer sensitive detail...
TP53 loss Ad5CMV-p53 gene colorectal cancer predicted - sensitive detail...
RET mutant Ponatinib colorectal cancer sensitive detail...
BRAF mutant Tovorafenib colorectal cancer sensitive detail...
PIK3CA E542K PD-0325901 + Pictilisib colorectal cancer sensitive detail...
BRAF V600E Regorafenib colorectal cancer sensitive detail...
BRAF V600E Trametinib colorectal cancer sensitive detail...
BRAF V600E Sorafenib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib colorectal cancer sensitive detail...
BRAF V600E Lapatinib + Panobinostat colorectal cancer sensitive detail...
BRAF V600E Gefitinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Erlotinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Encorafenib colorectal cancer sensitive detail...
BRAF V600E Refametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Panitumumab colorectal cancer sensitive detail...
PIK3CA E545K Dactolisib colorectal cancer sensitive detail...
APC inact mut Celecoxib + Erlotinib colorectal cancer sensitive detail...
APC inact mut Celecoxib colorectal cancer sensitive detail...
APC inact mut Sulindac colorectal cancer sensitive detail...
APC inact mut Erlotinib + Ibuprofen colorectal cancer sensitive detail...
APC inact mut Dasatinib colorectal cancer sensitive detail...
RET M918T Sorafenib colorectal cancer sensitive detail...
BRAF V600E Panitumumab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Selumetinib colorectal cancer sensitive detail...
APC inact mut XAV939 colorectal cancer sensitive detail...
APC inact mut PKF118-310 colorectal cancer sensitive detail...
APC inact mut CCT036477 colorectal cancer sensitive detail...
APC inact mut CCT070535 colorectal cancer sensitive detail...
APC inact mut CCT031374 colorectal cancer sensitive detail...
APC inact mut NC043 colorectal cancer sensitive detail...
CTNNB1 mutant BC21 colorectal cancer sensitive detail...
APC inact mut Pyrvinium colorectal cancer sensitive detail...
APC inact mut Niclosamide colorectal cancer sensitive detail...
NRAS wild-type Panitumumab colorectal cancer predicted - sensitive detail...
APC Q1338* JW67 colorectal cancer sensitive detail...
APC Q1338* JW74 colorectal cancer sensitive detail...
APC mutant JW74 colorectal cancer sensitive detail...
BRAF V600X Vemurafenib colorectal cancer no benefit detail...
BRAF V600X Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E CCT196969 colorectal cancer sensitive detail...
BRAF V600E CCT241161 colorectal cancer sensitive detail...
NRAS mutant Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer no benefit detail...
NRAS wild-type Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer predicted - sensitive detail...
PIK3CA H1047X Bevacizumab + Temsirolimus colorectal cancer predicted - resistant detail...
TP53 mutant Pazopanib + Vorinostat colorectal cancer sensitive detail...
PIK3CA R88Q Cetuximab + Floxuridine + Fluorouracil + Irinotecan colorectal cancer predicted - sensitive detail...
PIK3CA E542K Cetuximab + Irinotecan colorectal cancer predicted - sensitive detail...
PIK3CA E542V Cetuximab colorectal cancer predicted - sensitive detail...
PIK3CA E545K Cetuximab + Irinotecan colorectal cancer sensitive detail...
PIK3CA H1047R Cetuximab colorectal cancer sensitive detail...
FGFR2 amp Debio 1347 colorectal cancer sensitive detail...
ARID1A Q456* Olaparib colorectal cancer sensitive detail...
APC mutant G-631 colorectal cancer no benefit detail...
ARID1A Q456* Talazoparib colorectal cancer sensitive detail...
MAP2K1 K57T Cetuximab colorectal cancer predicted - resistant detail...
MAP2K1 K57T Panitumumab colorectal cancer resistant detail...
MAP2K1 K57N Cetuximab colorectal cancer resistant detail...
MAP2K1 K57N Panitumumab colorectal cancer resistant detail...
MAP2K1 K57T Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57N Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57N Panitumumab + Trametinib colorectal cancer sensitive detail...
MAP2K1 K57T Panitumumab + Trametinib colorectal cancer sensitive detail...
ARID1A Q456* Rucaparib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Cetuximab colorectal cancer resistant detail...
BRAF V600E PIK3CA P449T Regorafenib colorectal cancer resistant detail...
BRAF V600E PIK3CA P449T Cetuximab + Regorafenib colorectal cancer sensitive detail...
BRAF V600E BI 882370 + Cetuximab colorectal cancer sensitive detail...
BRAF V600E Afatinib + BI 882370 colorectal cancer sensitive detail...
BRAF V600E BI 882370 + Trametinib colorectal cancer sensitive detail...
IDH1 R132H Metformin colorectal cancer sensitive detail...
IDH1 R132H AGI-5198 + Metformin colorectal cancer resistant detail...
IDH1 R132H AGI-5198 + Radiotherapy colorectal cancer resistant detail...
TP53 wild-type Prodigiosin colorectal cancer sensitive detail...
TP53 mutant Prodigiosin colorectal cancer sensitive detail...
TP53 loss Prodigiosin colorectal cancer sensitive detail...
BRAF V600E PD-0325901 colorectal cancer sensitive detail...
BRAF V600E SCH772984 colorectal cancer sensitive detail...
MLH1 inact mut N/A colorectal cancer not applicable detail...
FLT3 amp Sorafenib colorectal cancer predicted - sensitive detail...
MSH6 mutant N/A colorectal cancer not applicable detail...
BRAF V600E DT01 + Fluorouracil + Oxaliplatin colorectal cancer sensitive detail...
MAP2K1 F53L Trametinib colorectal cancer sensitive detail...
ATM loss Berzosertib colorectal cancer sensitive detail...
BRAF mutant Trametinib colorectal cancer resistant detail...
BRAF mutant Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF G596R PIK3CA E545K Neratinib colorectal cancer sensitive detail...
BARD1 inact mut Veliparib colorectal cancer predicted - sensitive detail...
APC mutant K-756 colorectal cancer predicted - sensitive detail...
BRAF V600E SHP099 colorectal cancer resistant detail...
BRAF V600E Vemurafenib colorectal cancer no benefit detail...
BRAF V600E Cetuximab + Selumetinib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Cetuximab + Selumetinib colorectal cancer resistant detail...
BRAF V600E BRAF amp Cetuximab + Selumetinib colorectal cancer resistant detail...
BRAF V600E Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib colorectal cancer sensitive detail...
BRAF V600E Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + SCH772984 colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Alpelisib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 L115P Cetuximab + Dabrafenib + SCH772984 colorectal cancer sensitive detail...
BRAF V600E MAP2K1 V211D Cetuximab + Encorafenib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D Cetuximab + Dabrafenib + Trametinib colorectal cancer resistant detail...
BRAF V600E MAP2K1 V211D SCH772984 colorectal cancer resistant detail...
BRAF V600E BRAF amp Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E BRAF amp SCH772984 colorectal cancer resistant detail...
MAP2K1 F129L RO4927350 colorectal cancer sensitive detail...
BRAF V600E PLX7904 colorectal cancer sensitive detail...
BRAF V600E TAK-632 colorectal cancer sensitive detail...
BRAF V600E PLX4720 + TAK-632 colorectal cancer sensitive detail...
ARID1A Q456* Dasatinib colorectal cancer sensitive detail...
BRAF V600E Lifirafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Lifirafenib colorectal cancer sensitive detail...
BRAF V600E Pimasertib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Pimasertib colorectal cancer sensitive detail...
BRAF V600E Everolimus + Pimasertib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Everolimus + Pimasertib colorectal cancer sensitive detail...
BRAF V600E Pimasertib + Sorafenib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Pimasertib + Sorafenib colorectal cancer sensitive detail...
BRAF V600E Pimasertib + Regorafenib colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T Pimasertib + Regorafenib colorectal cancer sensitive detail...
TP53 mutant NSC59984 colorectal cancer predicted - sensitive detail...
TP53 R175L NSC59984 colorectal cancer sensitive detail...
TP53 R175H NSC59984 colorectal cancer sensitive detail...
TP53 R273H TP53 P309S NSC59984 colorectal cancer sensitive detail...
TP53 R273H TP53 P309S Cisplatin + NSC59984 colorectal cancer sensitive detail...
BRAF V600E PIK3CA P449T TP53 R273H PD-0325901 + Sapanisertib colorectal cancer sensitive detail...
BRAF V600E PIK3CA H1047R TP53 wild-type PD-0325901 + Sapanisertib colorectal cancer sensitive detail...
BRAF V600E PTEN loss TP53 wild-type PD-0325901 + Sapanisertib colorectal cancer sensitive detail...
TP53 wild-type PD-0325901 + Sapanisertib colorectal cancer predicted - sensitive detail...
PIK3CA mutant MS417 + Pictilisib colorectal cancer predicted - sensitive detail...
BRAF mutant PLX4720 colorectal cancer decreased response detail...
BRAF mutant AZ628 + Selumetinib colorectal cancer sensitive detail...
APC wild-type TASIN-1 colorectal cancer resistant detail...
APC inact mut TASIN-1 colorectal cancer sensitive detail...
APC E1309* TASIN-1 colorectal cancer sensitive detail...
APC E853* APC K1555* TASIN-1 colorectal cancer sensitive detail...
APC Q1131* APC Q1303* TASIN-1 colorectal cancer sensitive detail...
APC Q1338* TASIN-1 colorectal cancer sensitive detail...
APC L1488* TASIN-1 colorectal cancer sensitive detail...
APC G1416* TASIN-1 colorectal cancer sensitive detail...
FGFR2 over exp Aprutumab ixadotin colorectal cancer sensitive detail...
APC inact mut PTEN inact mut Dactolisib colorectal cancer sensitive detail...
APC inact mut PTEN inact mut Binimetinib colorectal cancer no benefit detail...
APC inact mut PTEN inact mut Binimetinib + Dactolisib colorectal cancer no benefit detail...
PIK3CA H1047R Metformin colorectal cancer sensitive detail...
BRAF mut TP53 wild-type CGM097 + Dabrafenib + Navitoclax + PF-04217903 colorectal cancer sensitive detail...
BRAF mut TP53 mut Alpelisib + Dabrafenib + Erlotinib + Navitoclax colorectal cancer sensitive detail...
TP53 loss Ceralasertib + Radiotherapy colorectal cancer sensitive detail...
BRAF act mut VX-11e + WEHI-539 colorectal cancer predicted - sensitive detail...
BRAF act mut Venetoclax + VX-11e colorectal cancer no benefit detail...
MAP2K1 F53L Cetuximab colorectal cancer resistant detail...
MAP2K1 C121S Cetuximab colorectal cancer resistant detail...
MAP2K1 F53L Cetuximab + Trametinib colorectal cancer sensitive detail...
MAP2K1 C121S Cetuximab + Trametinib colorectal cancer sensitive detail...
NRAS G12V Cetuximab + Trametinib colorectal cancer sensitive detail...
NRAS G12V Cetuximab colorectal cancer resistant detail...
TP53 loss PHA-680632 + Radiotherapy colorectal cancer sensitive detail...
BRAF mutant Binimetinib colorectal cancer predicted - sensitive detail...
APC S811* G007-LK colorectal cancer sensitive detail...
APC S1197* APC S1278* G007-LK colorectal cancer sensitive detail...
APC L665* APC R1450* G007-LK colorectal cancer resistant detail...
APC E853* APC T1556fs G007-LK colorectal cancer resistant detail...
APC N1819fs APC wild-type G007-LK colorectal cancer resistant detail...
APC S811* IWR-1 colorectal cancer sensitive detail...
APC S1197* APC S1278* IWR-1 colorectal cancer sensitive detail...
APC E853* APC T1556fs IWR-1 colorectal cancer resistant detail...
APC L665* APC R1450* IWR-1 colorectal cancer sensitive detail...
APC N1819fs IWR-1 colorectal cancer resistant detail...
APC S811* XAV939 colorectal cancer sensitive detail...
APC S1197* APC S1278* XAV939 colorectal cancer sensitive detail...
APC N1819fs APC wild-type XAV939 colorectal cancer resistant detail...
APC L665* APC R1450* XAV939 colorectal cancer sensitive detail...
APC E853* APC T1556fs XAV939 colorectal cancer resistant detail...
APC R216* G007-LK colorectal cancer sensitive detail...
APC R216* IWR-1 colorectal cancer sensitive detail...
APC I1164fs G007-LK colorectal cancer sensitive detail...
APC I1164fs IWR-1 colorectal cancer sensitive detail...
APC W553* IWR-1 colorectal cancer sensitive detail...
APC W553* G007-LK colorectal cancer sensitive detail...
TP53 wild-type MK-8745 colorectal cancer predicted - sensitive detail...
IDH2 R172K Enasidenib colorectal cancer predicted - sensitive detail...
NRAS mut PIK3CA wild-type TAK-733 colorectal cancer predicted - sensitive detail...
BRAF mut PIK3CA wild-type TAK-733 colorectal cancer predicted - sensitive detail...
TP53 del Doxorubicin + Seliciclib colorectal cancer predicted - sensitive detail...
BRAF V600E PIK3CA mut ASN003 colorectal cancer sensitive detail...
TP53 wild-type ALRN-6924 colorectal cancer predicted - sensitive detail...
PTEN loss AZD8186 + Vistusertib colorectal cancer sensitive detail...
FGFR2 amp Erdafitinib colorectal cancer sensitive detail...
BRAF mutant Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF G596R Trametinib colorectal cancer sensitive detail...
BRAF G466V Cetuximab colorectal cancer sensitive detail...
BRAF G466V Trametinib colorectal cancer sensitive detail...
BRAF G466V Vemurafenib colorectal cancer predicted - resistant detail...
BRAF G466V Irinotecan + Panitumumab colorectal cancer not predictive detail...
BRAF G596R Vemurafenib colorectal cancer resistant detail...
BRAF mutant KO-947 colorectal cancer predicted - sensitive detail...
NRAS mutant KO-947 colorectal cancer predicted - sensitive detail...
PIK3CA K944N Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA V955G Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA V955I Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA K966E Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA E542K Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA E545K Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA H1047R Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA F930S Cetuximab + Fluorouracil colorectal cancer resistant detail...
PIK3CA V952A Cetuximab + Fluorouracil colorectal cancer resistant detail...
BRAF G596R Dabrafenib + Trametinib colorectal cancer sensitive detail...
ARID1A Q456* VE-821 colorectal cancer sensitive detail...
ARID1A Q456* Berzosertib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + PLX4720 colorectal cancer sensitive detail...
BRAF mutant Dabrafenib + Panitumumab + Trametinib colorectal cancer predicted - sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib colorectal cancer sensitive detail...
FBXW7 R505C Regorafenib colorectal cancer resistant detail...
BRAF V600E INU-152 colorectal cancer sensitive detail...
BRAF mutant LSN3074753 colorectal cancer predicted - sensitive detail...
BRAF V600E LSN3074753 colorectal cancer predicted - sensitive detail...
BRAF mutant Cetuximab + LSN3074753 colorectal cancer sensitive detail...
BRAF G596V NRAS G13R Cetuximab + LSN3074753 colorectal cancer sensitive detail...
BRAF V600E EBI-907 colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Panitumumab + Trametinib colorectal cancer predicted - sensitive detail...
BRAF V600E Panitumumab + Trametinib colorectal cancer no benefit detail...
PIK3CA mutant Alpelisib colorectal cancer sensitive detail...
NRAS mutant SYM004 colorectal cancer predicted - resistant detail...
BRAF mutant SYM004 colorectal cancer predicted - resistant detail...
BRAF V600E Binimetinib + Cetuximab + Encorafenib colorectal cancer sensitive detail...
BRAF mutant Belvarafenib colorectal cancer sensitive detail...
NRAS mutant Regorafenib colorectal cancer no benefit detail...
BRAF mutant Regorafenib colorectal cancer no benefit detail...
BRAF V600E Ulixertinib colorectal cancer sensitive detail...
BRAF G596R RMC-4550 colorectal cancer predicted - sensitive detail...
TP53 R248Q Tanespimycin colorectal cancer sensitive detail...
TP53 del Tanespimycin colorectal cancer decreased response detail...
TP53 R248Q Napabucasin colorectal cancer predicted - sensitive detail...
BRAF V600E NRAS Q61K Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V600E BRAF amp Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V47_D380del BRAF V600E Alpelisib + Cetuximab + Encorafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS G13R Alpelisib + Cetuximab + Encorafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS amp Panitumumab + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V600E NRAS over exp Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF V600E NRAS over exp BGB659 + Cetuximab colorectal cancer sensitive detail...
BRAF V600E NRAS G13R BGB659 + Cetuximab colorectal cancer predicted - sensitive detail...
NRAS G12X Cetuximab colorectal cancer resistant detail...
NRAS G13X Cetuximab colorectal cancer resistant detail...
NRAS A59X Cetuximab colorectal cancer resistant detail...
NRAS Q61X Cetuximab colorectal cancer resistant detail...
NRAS K117X Cetuximab colorectal cancer resistant detail...
NRAS A146X Cetuximab colorectal cancer resistant detail...
NRAS A146X Panitumumab colorectal cancer resistant detail...
NRAS A59X Panitumumab colorectal cancer resistant detail...
NRAS G12X Panitumumab colorectal cancer resistant detail...
NRAS G13X Panitumumab colorectal cancer resistant detail...
NRAS K117X Panitumumab colorectal cancer resistant detail...
NRAS Q61X Panitumumab colorectal cancer resistant detail...
APC dec exp G007-LK colorectal cancer predicted - sensitive detail...
APC L852* G007-LK colorectal cancer predicted - resistant detail...
APC Q886* G007-LK colorectal cancer conflicting detail...
CTNNB1 S33F G007-LK colorectal cancer predicted - resistant detail...
APC Q1406* G007-LK colorectal cancer predicted - sensitive detail...
APC E582fs G007-LK colorectal cancer predicted - resistant detail...
APC Q886* XAV939 colorectal cancer predicted - resistant detail...
APC Q1406* XAV939 colorectal cancer predicted - sensitive detail...
APC Q1406* NVP-TNKS656 colorectal cancer predicted - sensitive detail...
APC Q886* NVP-TNKS656 colorectal cancer predicted - resistant detail...
FGFR2 amp Zotatifin colorectal cancer sensitive detail...
IDH1 R132H Talazoparib colorectal cancer predicted - sensitive detail...
IDH1 R132H Olaparib colorectal cancer predicted - sensitive detail...
FGFR2 amp Regorafenib colorectal cancer predicted - sensitive detail...
ARID1A mutant unspecified PD-L1 antibody colorectal cancer predicted - sensitive detail...
ARID1A mutant unspecified PD-1 antibody colorectal cancer predicted - sensitive detail...
BRAF mutant SY-5609 colorectal cancer predicted - sensitive detail...
NRAS G115Efs*46 Cetuximab colorectal cancer predicted - resistant detail...
NRAS G115Efs*46 Panitumumab colorectal cancer predicted - resistant detail...
BRAF V600E Ravoxertinib colorectal cancer predicted - sensitive detail...
BRAF G596R PIK3CA E545K Vemurafenib colorectal cancer resistant detail...
BRAF V600E PIK3CA H1047R Vemurafenib colorectal cancer resistant detail...
BRAF V600E PIK3CA H1047R MK2206 + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E PIK3CA H1047R MK2206 colorectal cancer predicted - sensitive detail...
BRAF V600E Capecitabine + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Bevacizumab + Capecitabine + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Irinotecan + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Irinotecan + Vemurafenib colorectal cancer sensitive detail...
ARID1A loss Berzosertib colorectal cancer sensitive detail...
BRAF G596R PLX8394 colorectal cancer predicted - sensitive detail...
BRAF K601E PLX8394 colorectal cancer predicted - sensitive detail...
BRAF K601E Vemurafenib colorectal cancer resistant detail...
BRAF K601E Cetuximab colorectal cancer resistant detail...
BRAF K601E Cetuximab + Vemurafenib colorectal cancer resistant detail...
BRAF K601E Cetuximab + PLX8394 colorectal cancer sensitive detail...
BRAF G466V PLX8394 colorectal cancer resistant detail...
BRAF G466V Cetuximab + PLX8394 colorectal cancer sensitive detail...
BRAF G466V Cetuximab + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E BI-3406 colorectal cancer predicted - resistant detail...
BRAF T119S BRAF V600E BI-3406 colorectal cancer predicted - resistant detail...
CDKN2A hypermethylation N/A colorectal cancer not applicable detail...
BRAF V600E Chloroquine + Trametinib colorectal cancer sensitive detail...
CTNNB1 T41A Cetuximab colorectal cancer resistant detail...
CTNNB1 S45F Cetuximab colorectal cancer resistant detail...
CTNNB1 S33P Cetuximab colorectal cancer resistant detail...
BRAF V600E unspecified immune checkpoint inhibitor colorectal cancer decreased response detail...
MSH6 loss unspecified immune checkpoint inhibitor colorectal cancer predicted - sensitive detail...
BRAF V600E Lifirafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + Regorafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + RAF709 + Trametinib colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + LXH 254 + Trametinib colorectal cancer sensitive detail...
NRAS G12D GI-4000 colorectal cancer predicted - sensitive detail...
BRAF V600E JSI-1187 colorectal cancer predicted - sensitive detail...
BRAF V600E Dabrafenib + JSI-1187 colorectal cancer predicted - sensitive detail...
NRAS Q61X Binimetinib colorectal cancer unknown detail...
NRAS Q61R Binimetinib colorectal cancer predicted - sensitive detail...
NRAS Q61K Binimetinib colorectal cancer predicted - sensitive detail...
BRAF V600E Belvarafenib colorectal cancer predicted - sensitive detail...
BRAF T119S BRAF V600E LY3214996 colorectal cancer predicted - sensitive detail...
MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G LY3214996 colorectal cancer predicted - sensitive detail...
BRAF V600E LY3214996 colorectal cancer predicted - sensitive detail...
BRAF V600E ERAS-007 colorectal cancer sensitive detail...
MLH1 negative Pembrolizumab colorectal cancer sensitive detail...
MSH6 negative Pembrolizumab colorectal cancer sensitive detail...
MAP2K1 P124S Cetuximab + Irinotecan colorectal cancer predicted - resistant detail...
PIK3CA P449T MK2206 colorectal cancer sensitive detail...
PIK3CA P449T ARQ 751 colorectal cancer sensitive detail...
PIK3CA P449T Miransertib colorectal cancer sensitive detail...
PIK3CA P449T GSK690693 colorectal cancer sensitive detail...
PIK3CA P449T Ipatasertib colorectal cancer predicted - sensitive detail...
NRAS mutant Cetuximab colorectal cancer no benefit detail...
NRAS mutant Panitumumab colorectal cancer no benefit detail...
MLH1 negative Ipilimumab + Nivolumab colorectal cancer sensitive detail...
MSH6 negative Ipilimumab + Nivolumab colorectal cancer sensitive detail...
MLH1 negative Nivolumab colorectal cancer sensitive detail...
MSH6 negative Nivolumab colorectal cancer sensitive detail...
NRAS K135N Cetuximab colorectal cancer predicted - sensitive detail...
NRAS mut TP53 mut Adavosertib colorectal cancer no benefit detail...
ATM S214fs Berzosertib + Irinotecan colorectal cancer predicted - sensitive detail...
TP53 Y220C PC14586 colorectal cancer predicted - sensitive detail...
BRAF act mut CC-91516 colorectal cancer predicted - sensitive detail...
NRAS Q61K Palbociclib + Trametinib colorectal cancer sensitive detail...
APC S811* STP1002 colorectal cancer sensitive detail...
APC E1309Dfs*4 STP1002 colorectal cancer sensitive detail...
APC Q1338* STP1002 colorectal cancer sensitive detail...
APC R1450* STP1002 colorectal cancer sensitive detail...
APC E853* APC T1556Nfs*3 STP1002 colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Encorafenib + Ulixertinib colorectal cancer predicted - sensitive detail...
TP53 del MK-8745 colorectal cancer predicted - sensitive detail...
NRAS wild-type Fluorouracil + Irinotecan + Leucovorin + Panitumumab colorectal cancer predicted - sensitive detail...
FGFR2 amp 3D185 colorectal cancer sensitive detail...
PTEN Y174H PTEN K263* Olaparib colorectal cancer predicted - sensitive detail...
PTEN Y174H PTEN K263* Rucaparib colorectal cancer predicted - sensitive detail...
PIK3CA N1044K Alpelisib colorectal cancer predicted - sensitive detail...
PIK3CA N1044K Taselisib colorectal cancer predicted - sensitive detail...
PIK3CA N1044K MK2206 colorectal cancer predicted - sensitive detail...
PIK3CA N1068Kfs*5 PTEN Y174H PTEN K263* Alpelisib colorectal cancer predicted - sensitive detail...
PIK3CA N1068Kfs*5 PTEN Y174H PTEN K263* Taselisib colorectal cancer predicted - sensitive detail...
BRAF D594G Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer not predictive detail...
BRAF D594G Fluorouracil + Irinotecan + Leucovorin + Panitumumab colorectal cancer not predictive detail...
BRAF D594G Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab colorectal cancer not predictive detail...
BRAF D594G Cetuximab + Irinotecan colorectal cancer not predictive detail...
BRAF D594G Irinotecan + Panitumumab colorectal cancer not predictive detail...
BRAF D594N Irinotecan + Panitumumab colorectal cancer not predictive detail...
BRAF F247L Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer not predictive detail...
BRAF F595L Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab colorectal cancer not predictive detail...
BRAF G466E Irinotecan + Panitumumab colorectal cancer not predictive detail...
BRAF N581I Cetuximab + Irinotecan colorectal cancer not predictive detail...
BRAF N581S Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer not predictive detail...
BRAF N581T Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab colorectal cancer not predictive detail...
BRAF D594N Cetuximab colorectal cancer not predictive detail...
BRAF R558Q Cetuximab + Irinotecan colorectal cancer not predictive detail...
BRAF T599dup Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab colorectal cancer predicted - resistant detail...
BRAF T599dup Cetuximab colorectal cancer resistant detail...
BRAF G469A Cetuximab colorectal cancer not predictive detail...
BRAF G469A Cetuximab + Fluorouracil + Irinotecan + Leucovorin colorectal cancer not predictive detail...
BRAF G469A Cetuximab + Irinotecan colorectal cancer not predictive detail...
BRAF G469A Irinotecan + Panitumumab colorectal cancer not predictive detail...
BRAF G469V Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab colorectal cancer not predictive detail...
BRAF G469V Cetuximab + Irinotecan colorectal cancer not predictive detail...
BRAF K601E Panitumumab colorectal cancer predicted - resistant detail...
BRAF L485F Cetuximab + Irinotecan colorectal cancer not predictive detail...
BRAF L525R Cetuximab colorectal cancer not predictive detail...
BRAF L597R Fluorouracil + Irinotecan + Leucovorin + Panitumumab colorectal cancer not predictive detail...
BRAF V600E Pyrvinium + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Axitinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Panobinostat + Trametinib colorectal cancer sensitive detail...
BRAF V600E Trametinib + Vorinostat colorectal cancer sensitive detail...
BRAF V600E Romidepsin + Trametinib colorectal cancer sensitive detail...
BRAF V600E Mocetinostat + Trametinib colorectal cancer sensitive detail...
BRAF V600E Entinostat + Trametinib colorectal cancer sensitive detail...
BRAF V600E Trametinib + Valproic acid colorectal cancer sensitive detail...
BRAF V600E Panobinostat + Vemurafenib colorectal cancer sensitive detail...
BRAF class 2 Cetuximab colorectal cancer decreased response detail...
BRAF class 2 Panitumumab colorectal cancer decreased response detail...
NRAS exon2 Cetuximab colorectal cancer resistant detail...
NRAS exon4 Panitumumab colorectal cancer resistant detail...
NRAS exon3 Panitumumab colorectal cancer resistant detail...
NRAS exon3 Cetuximab colorectal cancer resistant detail...
NRAS exon4 Cetuximab colorectal cancer resistant detail...
NRAS exon2 Panitumumab colorectal cancer resistant detail...
BRAF V600E Cetuximab colorectal cancer resistant detail...
BRAF V600E Panitumumab colorectal cancer resistant detail...
BRAF V600E Dabrafenib + Spartalizumab + Trametinib colorectal cancer sensitive detail...
BRAF V600E Saracatinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Dasatinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Bosutinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Dasatinib + Gefitinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Dasatinib + Gefitinib + PLX4720 colorectal cancer sensitive detail...
BRAF V600E Gefitinib + PLX4720 + Saracatinib colorectal cancer sensitive detail...
BRAF V600E Celecoxib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Celecoxib + Gefitinib + Trametinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Celecoxib + Trametinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Celecoxib + Dabrafenib + Trametinib colorectal cancer sensitive detail...
BRAF V600E Celecoxib + Dabrafenib + Panitumumab + Trametinib colorectal cancer sensitive detail...
BRAF V600E Celecoxib + Encorafenib + Panitumumab colorectal cancer sensitive detail...
BRAF act mut BCA101 colorectal cancer sensitive detail...
BRAF V600E Binimetinib + Encorafenib + PF-07284892 colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Encorafenib + PF-07284892 colorectal cancer predicted - sensitive detail...
BRAF V600E Cetuximab + Encorafenib + ERAS-007 colorectal cancer predicted - sensitive detail...
BRAF V600E Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin colorectal cancer no benefit detail...
BRAF V600E Binimetinib + Trifluridine-tipiracil hydrochloride colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Fluorouracil + Leucovorin + Vemurafenib colorectal cancer no benefit detail...
BRAF V600E MAP2K1 K57T Cetuximab + Fluorouracil + Leucovorin + Vemurafenib colorectal cancer predicted - resistant detail...
BRAF V600E SJ-C1044 colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin colorectal cancer sensitive detail...
BRAF V600E Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin colorectal cancer sensitive detail...
BRAF V600X Tunlametinib + Vemurafenib colorectal cancer predicted - sensitive detail...
PIK3CA H1047R Alpelisib colorectal cancer resistant detail...
APC S1356* G007-LK colorectal cancer sensitive detail...
APC Q1367* G007-LK colorectal cancer resistant detail...
APC R499* G007-LK colorectal cancer sensitive detail...
APC R876* G007-LK colorectal cancer sensitive detail...
APC Q1378* G007-LK colorectal cancer sensitive detail...
APC L1489* G007-LK colorectal cancer sensitive detail...
APC L954* G007-LK colorectal cancer sensitive detail...
APC I1287Rfs*3 G007-LK colorectal cancer sensitive detail...
APC L1302Rfs*3 G007-LK colorectal cancer resistant detail...
APC G1116Efs*6 G007-LK colorectal cancer sensitive detail...
APC K670* G007-LK colorectal cancer sensitive detail...
APC Y935* APC L1489Yfs*18 G007-LK colorectal cancer sensitive detail...
APC S1421Rfs*52 G007-LK colorectal cancer sensitive detail...
APC L665Ifs*8 APC R1450* G007-LK colorectal cancer resistant detail...
APC E633* APC E1494* APC Q1529* G007-LK colorectal cancer sensitive detail...
APC S299Tfs*7 APC R805* G007-LK colorectal cancer sensitive detail...
APC V830Gfs*12 APC T1556Nfs*3 G007-LK colorectal cancer resistant detail...
APC S1465Wfs*3 APC T1556Nfs*3 G007-LK colorectal cancer sensitive detail...
APC R499* APC E1295* G007-LK colorectal cancer sensitive detail...
APC R216* G007-LK + Trametinib colorectal cancer sensitive detail...
APC R302* APC E1345* G007-LK + Trametinib colorectal cancer sensitive detail...
APC E941* APC T1459fs G007-LK + Trametinib colorectal cancer sensitive detail...
APC R876* Buparlisib + G007-LK colorectal cancer sensitive detail...
BRAF V600E IMM-6-415 colorectal cancer predicted - sensitive detail...
BRAF V600E Encorafenib + IMM-6-415 colorectal cancer predicted - sensitive detail...
NRAS G12C Panitumumab + Sotorasib colorectal cancer predicted - sensitive detail...
ATM S214Ffs*40 ATM loss ART0380 colorectal cancer sensitive detail...
ATM S214Pfs*16 ART0380 colorectal cancer sensitive detail...
ATM M779I ART0380 colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + IAG933 colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + IAG933 + LTT462 colorectal cancer sensitive detail...
BRAF V600E Dabrafenib + IAG933 + Trametinib colorectal cancer sensitive detail...
PIK3CA mutant Copanlisib + Nivolumab colorectal cancer predicted - sensitive detail...
FLT3 amp Sunitinib colorectal cancer no benefit detail...
BRAF V600E Tunlametinib + Vemurafenib colorectal cancer sensitive detail...
BRAF V600E Tunlametinib colorectal cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00063141 Phase III Irinotecan Cetuximab + Irinotecan Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer Completed USA | NLD | ITA | GBR | FRA | DEU | BEL | AUT | AUS 8
NCT00433927 Phase III Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) Unknown status DEU 0
NCT00442637 Phase III Bevacizumab + Capecitabine Maintenance Treatment Versus Observation After Induction in Advanced Colorectal Carcinoma (CAIRO3) Unknown status NLD 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT00730158 Phase II Irinotecan YIV-906 A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer Completed USA 0
NCT00940316 Phase II Irinotecan Erlotinib + Panitumumab Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Completed USA 0
NCT00940381 Phase I Cetuximab + Sirolimus Sirolimus and Cetuximab in Advanced Malignancies Completed USA 0
NCT00996892 Phase I Cobimetinib + Pictilisib Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors Terminated USA 0
NCT01006369 Phase II Hydroxychloroquine Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Completed USA 0
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Completed USA 0
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01218867 Phase Ib/II Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes Terminated USA 0
NCT01260415 Phase II Panitumumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases Completed CAN 0
NCT01294826 Phase I Cetuximab + Luminespib Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed USA 0
NCT01312857 Phase II Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer Active, not recruiting USA 0
NCT01327612 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab Open Label Extension Study of Conatumumab and AMG 479 Completed USA | ESP 1
NCT01340300 Phase II Metformin Exercise and Metformin in Colorectal and Breast Cancer Survivors Completed USA 0
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Active, not recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN 0
NCT01358331 Phase I MK-8353 A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) Terminated 0
NCT01436656 Phase I Encorafenib A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma Completed USA | FRA | ESP | AUS 3
NCT01543698 Phase Ib/II Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors Completed USA | ITA | FRA | ESP | CAN | BEL | AUS 2
NCT01562899 Phase II Binimetinib + Ganitumab A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 0
NCT01569984 Phase II Bevacizumab Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis Completed CAN 0
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | NLD | GBR | FRA | ESP | AUS 1
NCT01591421 Phase Ib/II Buparlisib + Panitumumab P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer. Completed CAN 0
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | CAN 1
NCT01607957 Phase III Trifluridine-tipiracil hydrochloride Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies (RECOURSE) Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 4
NCT01661972 Phase Ib/II Aflibercept + Capecitabine Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer Completed USA 0
NCT01669720 Phase II Aflibercept Adjuvant Aflibercept for Metastatic Colorectal Cancer Terminated USA 0
NCT01676714 Phase II Dovitinib Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Completed USA 0
NCT01703390 Phase II Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Biomarker Directed Treatment in Metastatic Colorectal Cancer Completed AUT 0
NCT01719380 Phase Ib/II Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 3
NCT01722162 Phase II Bevacizumab + Capecitabine Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Completed USA 0
NCT01729923 Phase II Capecitabine Celecoxib A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer Terminated USA 0
NCT01750918 Phase II Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) Completed USA | NLD | ITA | GBR | FRA | ESP | BEL 1
NCT01765582 Phase II Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer Terminated USA 0
NCT01776307 Phase II Cetuximab + Napabucasin Capecitabine + Napabucasin Napabucasin + Panitumumab A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Completed USA 0
NCT01792934 Capecitabine + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases (ORCHESTRA) Recruiting NLD | GBR 0
NCT01871311 Phase I Cetuximab + Nilotinib A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab Terminated USA 0
NCT01874860 Phase I Doxycycline Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients Completed USA 0
NCT01876511 Phase II Pembrolizumab Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors Completed USA 0
NCT01888965 Phase II Dovitinib Maintenance Dovitinib for Colorectal and Pancreas Cancer Terminated USA 0
NCT01923337 Phase I Alisertib + Irinotecan Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer Completed USA 0
NCT01927341 Phase Ib/II Binimetinib Panitumumab Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors Completed USA | NLD | ITA | FRA | ESP | CAN | BEL 0
NCT01937715 Phase II Bevacizumab Gedatolisib Fluorouracil + Irinotecan + Leucovorin A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer Terminated USA | ESP | CAN 0
NCT01939223 Phase III Regorafenib COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 5
NCT01952730 Phase I GVAX colorectal cancer vaccine GVAX for Colorectal Cancer Terminated USA 0
NCT01960023 Phase Ib/II Cetuximab + Neratinib Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer Withdrawn USA 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA | NLD | AUS 0
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 5
NCT01974258 Phase I Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients Withdrawn USA 0
NCT01988896 Phase I Atezolizumab + Cobimetinib A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors Completed USA | DEU | CAN | AUS 2
NCT02004106 Phase I Cergutuzumab amunaleukin A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed USA | NLD | GBR | FRA | ESP 3
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Active, not recruiting USA 0
NCT02025803 Phase I Capecitabine + TAS-114 A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Completed USA 0
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn USA 0
NCT02041481 Phase I Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer Completed USA 0
NCT02060188 Phase Ib/II Nivolumab Ipilimumab A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 1
NCT02083653 Phase II SYM004 Fluorouracil Capecitabine Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer Completed USA | ITA | FRA | ESP | DEU | BEL | AUT 3
NCT02110082 Phase I Cetuximab + Urelumab Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Completed USA 0
NCT02122809 Phase I Chiauranib Phase I Study of Chiauranib in Patients With Advanced Solid Tumors Completed 1
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Completed USA 0
NCT02141295 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin RO5520985 Bevacizumab + Fluorouracil + Leucovorin Fluorouracil + Leucovorin + RO5520985 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE) Terminated USA | GBR | FRA | ESP | BEL | AUT | AUS 0
NCT02162563 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5) Recruiting NLD | BEL 0
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated USA 0
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Active, not recruiting USA | FRA | ESP | CAN 1
NCT02199223 Phase I Panitumumab + Regorafenib Regorafenib + Panitumumab Terminated USA 0
NCT02205398 Phase Ib/II Capmatinib + Cetuximab Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Terminated USA | ITA | FRA | ESP | DEU | CAN | BEL 0
NCT02227667 Phase II Durvalumab Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer Completed USA 0
NCT02260440 Phase II Azacitidine + Pembrolizumab A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer Completed USA 0
NCT02268825 Phase Ib/II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers Terminated USA 0
NCT02277093 Phase II Pacritinib Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer Terminated USA 0
NCT02278133 Phase Ib/II Cetuximab + Encorafenib + LGK974 Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations Completed USA | NLD | ITA | FRA | ESP | CAN | BEL | AUS 2
NCT02279433 Phase I Taletrectinib A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT02287025 FDA approved Regorafenib A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes? Terminated USA 0
NCT02298959 Phase I Aflibercept + Pembrolizumab Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors Active, not recruiting USA | CAN 0
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Completed 1
NCT02316340 Phase II Vorinostat Hydroxychloroquine Regorafenib Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer Completed USA 0
NCT02318901 Phase Ib/II Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer Terminated USA 0
NCT02327078 Phase Ib/II Epacadostat + Nivolumab A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers Completed USA | GBR 0
NCT02335918 Phase Ib/II Nivolumab + Varlilumab A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Completed USA 0
NCT02339116 Phase III Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC (TRIBE2) Unknown status ITA 0
NCT02346955 Phase I CM-24 CM-24 + Pembrolizumab Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) Terminated USA 1
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated USA | ESP 0
NCT02399943 Phase II Panitumumab + Trametinib A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer Completed CAN 0
NCT02402036 Phase II Regorafenib A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer Terminated USA 0
NCT02425683 Phase II Regorafenib Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX Terminated USA 0
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting USA 0
NCT02433626 Phase I COTI-2 Cisplatin + COTI-2 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) Unknown status USA 0
NCT02437071 Phase II Pembrolizumab Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients Active, not recruiting USA 0
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated USA 0
NCT02448810 Phase II Fluorouracil + Leucovorin Imalumab Panitumumab Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer Terminated USA 0
NCT02460198 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) Completed 0
NCT02460224 Phase Ib/II Ieramilimab Spartalizumab Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT02512172 Phase I Azacitidine + Pembrolizumab Pembrolizumab + Romidepsin Azacitidine + Pembrolizumab + Romidepsin A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer Completed USA 0
NCT02516553 Phase I BI 894999 BI 894999 First in Human Dose Finding Study in Advanced Malignancies Completed USA | FRA | ESP | DEU | BEL 1
NCT02526017 Phase I Cabiralizumab Nivolumab Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers Completed USA 0
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Completed USA | NLD | FRA | CAN 0
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated USA 0
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated USA | FRA 0
NCT02559024 Phase I MEDI6469 Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer Terminated USA 0
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Terminated USA 0
NCT02563002 Phase III Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Completed 0
NCT02568046 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + SYM004 Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients Terminated USA | ESP 0
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT02573220 Phase I Cetuximab + Fluorouracil + Irinotecan + Leucovorin Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer Withdrawn ITA 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed FRA | ESP 1
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Active, not recruiting USA | FRA | ESP | DEU 14
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Terminated USA 0
NCT02599324 Phase Ib/II Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Completed USA | GBR | ESP 1
NCT02600949 Phase I Pembrolizumab Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma Recruiting USA 0
NCT02605044 Phase III Masitinib Fluorouracil + Irinotecan + Leucovorin Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer Terminated GBR | FRA 1
NCT02613650 Phase I Binimetinib + Fluorouracil + Irinotecan + Leucovorin A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers Completed USA 0
NCT02630420 Phase I Cetuximab + Savolitinib Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Withdrawn 0
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting USA | CAN 2
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Completed USA 0
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Completed USA 0
NCT02654639 Phase II Bevacizumab + Trifluridine-tipiracil hydrochloride Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer Terminated USA 0
NCT02671955 Phase I Onvatilimab A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated USA 0
NCT02703571 Phase Ib/II Ribociclib + Trametinib Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors Terminated USA | NLD | ESP | DEU | CAN | BEL | AUS 0
NCT02713373 Phase Ib/II Cetuximab + Pembrolizumab Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery Completed USA 0
NCT02713529 Phase Ib/II AMG 820 + Pembrolizumab Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Completed USA | ESP | DEU | CAN | BEL | AUS 0
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Completed USA | NLD | ITA | FRA | ESP | CAN | AUS 2
NCT02745769 Phase I Merestinib + Ramucirumab Abemaciclib + Ramucirumab A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Completed USA | GBR | FRA 0
NCT02753127 Phase III Fluorouracil + Irinotecan + Leucovorin Napabucasin A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C) Completed USA | NLD | ITA | FRA | ESP | DEU | CAN | BEL | AUS 7
NCT02754856 Phase I Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases. Completed USA 0
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | BEL 0
NCT02785068 Phase I Fluorouracil + Irinotecan + Leucovorin + MM-151 Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer Withdrawn 0
NCT02811497 Phase II Azacitidine + Durvalumab Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) Completed CAN 0
NCT02837263 Phase I Pembrolizumab PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer Completed USA 0
NCT02857270 Phase I LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Completed USA | FRA | AUS 1
NCT02861300 Phase Ib/II Capecitabine + Telaglenastat CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer Active, not recruiting USA 0
NCT02870920 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies Completed CAN 0
NCT02873195 Phase II Bevacizumab + Capecitabine Atezolizumab + Bevacizumab + Capecitabine Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Terminated USA 0
NCT02888743 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Active, not recruiting USA | CAN 0
NCT02890069 Phase I LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Completed USA | NLD | GBR | ESP | DEU 2
NCT02900664 Phase I Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Completed USA | ITA | FRA | ESP | CAN | BEL 3
NCT02906059 Phase I Adavosertib + Irinotecan Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Completed USA 0
NCT02928224 Phase III Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT02934529 Phase III Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Capecitabine + Fluorouracil + Leucovorin Regorafenib Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114) Active, not recruiting DEU 0
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Completed USA | ITA | DEU | CAN | AUT 4
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Completed USA 0
NCT02959437 Phase Ib/II Azacitidine + Epacadostat + Pembrolizumab Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) Terminated USA | GBR | ESP 0
NCT02960594 Phase I INO-1400 + INO-9012 INO-1400 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Completed USA 0
NCT02961283 Phase I ASN003 Study of ASN003 in Subjects With Advanced Solid Tumors Terminated USA 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT02965417 Phase II SYM004 Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients Withdrawn 0
NCT02981524 Phase II Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer Completed USA 0
NCT02982694 Phase II Atezolizumab + Bevacizumab Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Terminated NLD | ITA | ESP | BEL 0
NCT02983578 Phase II Danvatirsen + Durvalumab AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer Active, not recruiting USA 0
NCT02991196 Phase I DS-8273a + Nivolumab Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer Terminated USA 0
NCT02992912 Phase II Atezolizumab Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) Active, not recruiting FRA 0
NCT03005002 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver Completed USA 0
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA | BEL 0
NCT03031691 Phase I Brontictuzumab + Trifluridine A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer Completed USA 0
NCT03035279 Phase I SC-006 A Study of SC-006 in Subjects With Advanced Cancer Terminated USA 0
NCT03050814 Phase II Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 Terminated USA 0
NCT03087591 Phase I APN401 APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Completed USA 0
NCT03096054 Phase I LY3143921 A CR-UK Phase I Trial of LY3143921 Active, not recruiting GBR 0
NCT03099486 Phase II Fluorouracil + Leucovorin + Regorafenib Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC Terminated USA 0
NCT03101475 Phase II Durvalumab + Tremelimumab Synergism of Immunomodulation and Tumor Ablation (ILOC) Completed NLD | FRA | DEU | AUT 2
NCT03122509 Phase II Durvalumab + Tremelimumab A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer Completed USA 0
NCT03184870 Phase Ib/II BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel BMS-813160 A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors Completed USA | ESP | DEU | CAN | BEL | AUS 0
NCT03188965 Phase I Elimusertib First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CAN 4
NCT03189030 Phase I pLADD Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer Terminated USA 0
NCT03203525 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Doxorubicin + Temsirolimus Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer Recruiting USA 0
NCT03206073 Phase Ib/II Durvalumab + Tremelimumab Durvalumab A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer Completed USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting NZL | FRA | ESP | AUS 5
NCT03215264 Phase Ib/II Entinostat + Hydroxychloroquine + Regorafenib Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer Completed USA 0
NCT03223779 Phase Ib/II Trifluridine Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer Recruiting USA 0
NCT03234712 Phase I ABBV-321 A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands Completed USA | AUS 1
NCT03239145 Phase I Pembrolizumab + Trebananib Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor Active, not recruiting USA 0
NCT03256344 Phase I Atezolizumab + Talimogene laherparepvec Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Completed USA | ESP | DEU | BEL | AUS 1
NCT03259867 Phase II Nivolumab Pembrolizumab Combination of TATE and PD-1 Inhibitor in Liver Cancer Recruiting USA 0
NCT03263429 Phase Ib/II Irinotecan + Panitumumab + Telaglenastat Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer Active, not recruiting USA 0
NCT03265080 Phase I ADXS-NEO Expressing Personalized Tumor Antigens Study Terminated USA 0
NCT03271047 Phase Ib/II Binimetinib + Ipilimumab + Nivolumab Binimetinib + Nivolumab Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation Completed USA | NLD | GBR | ESP | BEL 0
NCT03289962 Phase I Autogene cevumeran Atezolizumab + Autogene cevumeran A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Active, not recruiting USA | NLD | GBR | ESP | DEU | CAN | BEL 1
NCT03290937 Phase I Cetuximab + Irinotecan + Utomilumab Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer Active, not recruiting USA 0
NCT03307603 Phase Ib/II Nivolumab + Yttrium-90 microsphere therapy Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer Withdrawn 0
NCT03313778 Phase I mRNA-4157 + Pembrolizumab mRNA-4157 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603) Recruiting USA | AUS 0
NCT03319459 Phase I FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors Completed USA 0
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03340558 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER) Withdrawn USA 0
NCT03361228 Phase Ib/II Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors Terminated USA 0
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Terminated USA | CAN 0
NCT03374254 Phase I Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) Completed USA | CAN 0
NCT03391232 Phase I PolyPEPI1018 Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) Completed USA | ITA 0
NCT03403634 Phase I Celecoxib + Interferon alpha-2b + Rintatolimod Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Completed USA 0
NCT03407976 Phase Ib/II Pembrolizumab + Rivoceranib Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies Terminated USA 0
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Terminated USA | GBR | FRA | ESP 0
NCT03414983 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) Completed USA | ESP | CAN 2
NCT03415126 Phase I ERAS-007 A Study of ASN007 in Patients With Advanced Solid Tumors Completed USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU 2
NCT03428126 Phase II Durvalumab + Trametinib Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer Completed USA 0
NCT03428958 Phase I A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment Completed USA | GBR | FRA 0
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Terminated USA 0
NCT03439462 Phase Ib/II Bevacizumab + Fluorouracil + Leucovorin + Nab-rapamycin + Oxaliplatin ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer Completed USA 0
NCT03446157 Phase II Cetuximab + Palbociclib Palbociclib and Cetuximab in Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03457896 Phase II Cetuximab + Neratinib Neratinib + Trastuzumab Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status Unknown status USA 0
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Completed USA | CAN | AUS 2
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting USA 0
NCT03485209 Phase II Tisotumab vedotin-tftv Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN 1
NCT03519412 Phase II Pembrolizumab Temozolomide Pembrolizumab + Temozolomide Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA) Active, not recruiting ITA 0
NCT03520946 Phase III Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) Active, not recruiting DEU 0
NCT03526835 Phase I MCLA-158 A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Recruiting USA | NLD | GBR | FRA | ESP | BEL 0
NCT03530267 Phase II Fluorouracil + Leucovorin + Oxaliplatin Aflibercept + Fluorouracil + Leucovorin Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (ELDERLY) Completed DEU 0
NCT03531632 Phase Ib/II MGD007 + Retifanlimab MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer Completed USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03547999 Phase II Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CV301 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC Active, not recruiting USA 0
NCT03549338 Phase II Modotuximab Futuximab SYM004 Sym004 Versus Futuximab or Modotuximab in Patients With mCRC Terminated USA | ITA | ESP | DEU 0
NCT03555149 Phase Ib/II Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Terminated USA | FRA | AUS 2
NCT03563157 Phase Ib/II Aldoxorubicin + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin + Regorafenib + Trastuzumab Regorafenib QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine Active, not recruiting USA 0
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Completed USA | CAN 1
NCT03616574 Phase I CA102N CA102N + Trifluridine-tipiracil hydrochloride First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors Completed USA 0
NCT03628677 Phase I AB154 AB154 + Zimberelimab A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Active, not recruiting USA | AUS 0
NCT03629756 Phase I Etrumadenant + Zimberelimab A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Completed USA | AUS 0
NCT03631407 Phase II Pembrolizumab + Vicriviroc Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Completed USA | CAN 0
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Completed USA | AUS 0
NCT03656718 Phase Ib/II Nivolumab + rHuPH20 A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) Active, not recruiting USA | NZL | NLD | ITA | GBR | FRA | ESP 5
NCT03657641 Phase Ib/II Pembrolizumab + Regorafenib Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT03658772 Phase I Grapiprant + Pembrolizumab Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer Completed USA 0
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN | BEL 0
NCT03668431 Phase II Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib + PDR001 In Colorectal Cancer Recruiting USA 0
NCT03693170 Phase II Binimetinib + Cetuximab + Encorafenib Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC) Completed USA | NLD | ITA | GBR | FRA | ESP | BEL | AUT 1
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03714958 Phase I Siremadlin + Trametinib Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) Completed FRA 0
NCT03720678 Phase I Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies Completed USA | AUS 0
NCT03724071 Phase Ib/II Flucytosine + TG6002 Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. Terminated FRA | ESP | BEL 0
NCT03735628 Phase Ib/II Copanlisib + Nivolumab An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors Completed USA | CAN 0
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Active, not recruiting USA 0
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Completed USA | CAN 0
NCT03785210 Phase II Nivolumab + Tadalafil + Vancomycin Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers Completed USA 0
NCT03791398 Phase Ib/II Nivolumab + ONC201 BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC (379) Terminated USA 0
NCT03792724 Phase Ib/II Nivolumab + Urelumab Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) Unknown status ESP 0
NCT03795311 Phase Ib/II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) (FOLFIRINOX3) Active, not recruiting FRA 0
NCT03796884 Phase II Linaclotide Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Active, not recruiting USA 0
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 9
NCT03798626 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052 Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUS 7
NCT03802747 Phase I Durvalumab + Tremelimumab Durvalumab Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases Withdrawn 0
NCT03819387 Phase I NBF-006 A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Active, not recruiting USA 0
NCT03829462 Phase III Regorafenib Irinotecan + Regorafenib Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI) Recruiting FRA 0
NCT03844620 Phase II Regorafenib Trifluridine-tipiracil hydrochloride Regorafenib + Trifluridine-tipiracil hydrochloride Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT03844750 Phase II Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery Recruiting USA 0
NCT03851614 Phase II Cediranib + Durvalumab Durvalumab + Olaparib Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) Active, not recruiting CAN 0
NCT03865082 Phase II IMO-2125 + Ipilimumab + Nivolumab Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) Active, not recruiting USA 0
NCT03871959 Phase I Pembrolizumab + Xevinapant Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) Completed FRA 0
NCT03875313 Phase Ib/II Talazoparib + Telaglenastat Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Terminated USA 0
NCT03875820 Phase I Defactinib + RO5126766 Phase I Trial of Defactinib and VS-6766. (FRAME) Active, not recruiting GBR 0
NCT03879811 Phase II Nivolumab Temozolomide Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer Withdrawn 0
NCT03891953 Phase I DKY709 DKY709 + Spartalizumab Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. Active, not recruiting USA | ESP | DEU 3
NCT03900442 Phase I GGTI-2418 Phase 1 Study of PTX-100 in Patients With Advanced Malignancies Unknown status AUS 0
NCT03929666 Phase II Cisplatin + Gemcitabine Cisplatin + Fluorouracil + ZW25 Capecitabine + Oxaliplatin + ZW25 Fluorouracil + Leucovorin + Oxaliplatin + ZW25 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + ZW25 A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer Active, not recruiting USA | CAN 2
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03947385 Phase Ib/II IDE196 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Recruiting USA | CAN | AUS 0
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Completed USA 0
NCT03965845 Phase Ib/II Palbociclib + Telaglenastat A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Completed USA 0
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Suspended USA 0
NCT03981614 Phase II Trifluridine-tipiracil hydrochloride Binimetinib + Palbociclib Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer Active, not recruiting USA 0
NCT03983993 Phase II Niraparib + Panitumumab Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect) Active, not recruiting USA 0
NCT03990233 Phase I Effi-DEM Effi-DEM + Ezabenlimab A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Active, not recruiting FRA | BEL 0
NCT04000529 Phase I Spartalizumab + TNO155 Ribociclib + TNO155 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies Terminated USA | ESP | DEU | BEL | AUS 4
NCT04008030 Phase III Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT04008797 Phase I Lenvatinib E7386 + Lenvatinib A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor Recruiting USA | FRA 3
NCT04034459 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) Active, not recruiting DEU 0
NCT04041310 Phase I GAd-209-FSP + MVA-209-FSP Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors Recruiting USA | ITA | GBR | ESP | CAN | BEL 0
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP 0
NCT04046445 Phase Ib/II ATP128 + Ezabenlimab ATP128 ATP128 + Ezabenlimab + VSV-GP128 Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01) Active, not recruiting USA | DEU | BEL 1
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA | GBR 0
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Active, not recruiting USA 0
NCT04069026 Phase I BAY2416964 A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer Completed USA | GBR | ESP | DEU | CAN 0
NCT04072198 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR) Unknown status ITA 0
NCT04073615 Phase Ib/II Rivoceranib + Trifluridine-tipiracil hydrochloride Rivoceranib Trifluridine-tipiracil hydrochloride Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer Terminated USA 0
NCT04083599 Phase Ib/II GEN1042 GEN1042 Safety Trial in Subjects With Malignant Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP | DEU 6
NCT04096417 Phase II Pemigatinib Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations Active, not recruiting USA 0
NCT04108481 Phase Ib/II Durvalumab Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C) Suspended USA 0
NCT04117087 Phase I Ipilimumab + Nivolumab + Poly ICLC + Pooled Mutant KRAS-Targeted Long Peptide Vaccine Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer Recruiting USA 0
NCT04117958 Phase I AMG 199 Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers Terminated USA | NLD | FRA | ESP | DEU | AUT 3
NCT04130516 Phase Ib/II LNS8801 LNS8801 + Pembrolizumab Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab Recruiting USA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04140526 Phase Ib/II ONC-392 ONC-392 + Pembrolizumab Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Recruiting USA | AUS 0
NCT04145193 Phase II Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC Withdrawn 0
NCT04164069 Phase I Bevacizumab + Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab Active, not recruiting USA 0
NCT04166383 Phase II Nivolumab + VB-111 VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) Completed USA 0
NCT04172597 Phase II Poziotinib A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies Terminated USA 0
NCT04185883 Phase Ib/II Fluorouracil + Irinotecan + Panitumumab + Sotorasib AMG 404 + Sotorasib Carboplatin + Docetaxel + Paclitaxel + Pembrolizumab + Pemetrexed Disodium + Sotorasib Sotorasib + TNO155 Atezolizumab + Sotorasib Pembrolizumab + Sotorasib Sotorasib Everolimus + Sotorasib Bevacizumab-awwb + Fluorouracil + Oxaliplatin + Sotorasib Bevacizumab-awwb + Fluorouracil + Irinotecan + Sotorasib BI 1701963 + Sotorasib Palbociclib + Sotorasib Afatinib + Sotorasib RMC-4630 + Sotorasib Panitumumab + Sotorasib + Trametinib Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) Recruiting USA | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 3
NCT04189055 Phase II Cetuximab + Irinotecan Cetuximab Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL) Recruiting FRA 0
NCT04194034 Phase Ib/II Flucytosine + TG6002 Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer Terminated GBR | FRA 0
NCT04244552 Phase I ATRC-101 First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies Terminated USA 0
NCT04249843 Phase I BGB3245 Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors Recruiting USA | AUS 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04259450 Phase Ib/II AFM24 Study to Assess AFM24 in Advanced Solid Cancers Active, not recruiting USA | GBR | ESP | DEU 1
NCT04270864 Phase I IMO-2125 + Ipilimumab + Nivolumab Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) Active, not recruiting FRA 0
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) Terminated USA | CAN 1
NCT04330664 Phase Ib/II Adagrasib + TNO155 Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) Active, not recruiting USA 0
NCT04332653 Phase Ib/II NT-I7 + Pembrolizumab NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT04336241 Phase I Nivolumab + RP2 RP2 Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors Recruiting GBR | ESP 0
NCT04338685 Phase I RO7119929 + Tocilizumab A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases Completed USA | ESP 4
NCT04344795 Phase I TPST-1495 Pembrolizumab + TPST-1495 Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors Active, not recruiting USA 0
NCT04381650 Phase Ib/II Pembrolizumab + Subasumstat A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Active, not recruiting USA 8
NCT04421820 Phase I BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Active, not recruiting USA | CAN 1
NCT04425239 Phase II Fluorouracil + Irinotecan + Leucovorin + Panitumumab Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE) Completed ITA 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04430738 Phase Ib/II Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Recruiting USA 1
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04432857 Phase I E7046 + Pembrolizumab AN0025 and Pembrolizumab Combination in Advanced Solid Tumors Active, not recruiting USA | FRA 0
NCT04449874 Phase I Atezolizumab + Divarasib Bevacizumab + Divarasib Cetuximab + Divarasib Divarasib + Erlotinib Divarasib A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation Recruiting USA | NZL | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 9
NCT04450836 Phase II Regorafenib + Trifluridine-tipiracil hydrochloride Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) Active, not recruiting FRA | BEL 0
NCT04468607 Phase I BLYG8824A A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer Active, not recruiting USA | ESP | CAN | AUS 0
NCT04488003 Phase II Ulixertinib Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Terminated USA 0
NCT04505839 Phase I STP1002 First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors Completed USA 0
NCT04508140 Phase II BO-112 + Pembrolizumab Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis Terminated ITA | ESP | BEL 0
NCT04511039 Phase I Talazoparib + Trifluridine-tipiracil hydrochloride Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Recruiting USA 0
NCT04513951 Phase II Avelumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC) Active, not recruiting ITA 0
NCT04515394 Phase II Cetuximab + Tepotinib Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) Terminated USA | ITA | GBR | FRA | ESP | BEL 2
NCT04534218 Phase II Aspirin + Capecitabine + Cyclophosphamide + Regorafenib Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer (REPROGRAM-01) Completed FRA 0
NCT04535401 Phase I Elimusertib + Fluorouracil + Irinotecan + Leucovorin Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines Active, not recruiting USA 0
NCT04564898 Phase Ib/II Bevacizumab + Capecitabine + Trifluridine-tipiracil hydrochloride Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (TriComB) Recruiting ITA 0
NCT04585035 Phase Ib/II D-1553 Study to Evaluate D-1553 in Subjects With Solid Tumors Active, not recruiting USA | AUS 2
NCT04587128 Phase II Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC Recruiting USA 0
NCT04592653 Phase Ib/II ALKS 4230 ALKS 4230 + Pembrolizumab Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) Recruiting USA | ESP 0
NCT04595266 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + unspecified EGFR antibody Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + unspecified EGFR antibody Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL) Recruiting ESP 0
NCT04602117 Phase I Paclitaxel + Trastuzumab Duocarmazine Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Withdrawn USA 0
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) Active, not recruiting USA | GBR | CAN 1
NCT04607421 Phase III Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer Recruiting USA | NZL | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 19
NCT04609579 Phase I SNX281 Pembrolizumab + SNX281 Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma Terminated USA 0
NCT04616196 Phase Ib/II Cetuximab + NKTR-255 A Phase 1b/2 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Completed USA 0
NCT04622774 Phase I IMGC936 First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors Completed USA | ITA | ESP 0
NCT04645797 Phase I APR003 A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions Completed USA 0
NCT04659382 Phase II Atezolizumab + Bevacizumab + Capecitabine + Oxaliplatin Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI) Recruiting FRA 0
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP | CAN 0
NCT04683939 Phase Ib/II BNT141 BNT141 + Gemcitabine + Nab-paclitaxel Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors Terminated USA | CAN 0
NCT04701476 Phase II Pembrolizumab + Tirapazamine TATE and Pembrolizumab (MK3475) in mCRC and NSCLC Recruiting USA 1
NCT04704661 Phase I Ceralasertib + Trastuzumab deruxtecan Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Recruiting USA 0
NCT04705818 Phase II Durvalumab + Tazemetostat Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) Recruiting FRA 0
NCT04708470 Phase Ib/II Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Recruiting USA 0
NCT04713891 Phase I KF-0210 Atezolizumab + KF-0210 A Study of KF-0210 in Advanced Solid Tumors Patients Unknown status AUS 0
NCT04714983 Phase I DNX-2440 DNX-2440 for Resectable Colorectal Liver Metastasis Suspended USA 0
NCT04717375 Phase Ib/II BND-22 Study of BND-22 in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04761614 Phase I Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Riluzole Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT04776655 Phase III Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) Unknown status ITA 0
NCT04787341 Phase II Regorafenib Panitumumab PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) Recruiting ITA 0
NCT04795661 Phase II Pembrolizumab Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) Active, not recruiting FRA 0
NCT04800822 Phase I PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 PF-07284892 in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT04808362 Phase Ib/II OMO-103 Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) Terminated ESP 0
NCT04836195 Phase I PCLX-001 Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma Recruiting CAN 0
NCT04837196 Phase Ib/II ASP7517 + Pembrolizumab ASP7517 Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen Active, not recruiting USA 0
NCT04844073 Phase Ib/II MVC-101 A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer Recruiting USA | AUS 1
NCT04854434 Phase II Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations Terminated USA 0
NCT04870034 Phase I Binimetinib + Palbociclib Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer Withdrawn USA 0
NCT04874207 FDA approved Regorafenib Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib (RePERSO) Recruiting FRA 0
NCT04892017 Phase Ib/II DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Recruiting USA 0
NCT04895722 Phase II MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 13
NCT04903873 Phase Ib/II EU101 A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors Recruiting USA 1
NCT04907539 Phase II Denosumab + Nivolumab + RXC004 Denosumab + RXC004 A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) Completed USA | GBR | ESP 1
NCT04914286 Phase Ib/II GFH018 + Toripalimab-tpzi A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Completed AUS 1
NCT04916236 Phase I LY3214996 + RMC-4630 Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) Recruiting NLD 0
NCT04943900 Phase I BMS-986416 + Nivolumab BMS-986416 A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors Active, not recruiting USA | NLD | CAN | BEL 3
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Recruiting USA | NLD | ITA | ESP | BEL 1
NCT04969835 Phase I AVA6000 A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours Recruiting USA | GBR 0
NCT04973163 Phase I BI 1823911 + Midazolam BI 1701963 + BI 1823911 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Active, not recruiting USA | GBR | ESP | BEL 0
NCT04976634 Phase II Belzutifan + Lenvatinib + Pembrolizumab Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) Recruiting USA | NZL | NLD | FRA | ESP | BEL | AUS 3
NCT04989387 Phase I INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 Study of INCA 0186 in Subjects With Advanced Solid Tumors Active, not recruiting USA | NLD | GBR | ESP | BEL | AUT 0
NCT04991740 Phase I JNJ-78306358 A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors Completed ESP 1
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Recruiting USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 1
NCT05007132 Phase II Bevacizumab + Trifluridine-tipiracil hydrochloride Panitumumab + Trifluridine-tipiracil hydrochloride Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer Recruiting DEU 0
NCT05029882 Phase I ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab Recruiting USA | FRA | ESP | AUS 6
NCT05039177 Phase Ib/II Cetuximab + Encorafenib + ERAS-007 ERAS-007 + Palbociclib A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) Active, not recruiting USA 0
NCT05041972 Phase II ARX-788 ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) Withdrawn USA 0
NCT05047536 Phase I KZR-261 KZR-261 in Subjects With Advanced Solid Malignancies Recruiting USA 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05061017 Phase II Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) Active, not recruiting USA 0
NCT05061537 Phase I PF-06801591 + PF-07263689 PF-07263689 Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Terminated USA 0
NCT05062317 Phase II Capecitabine Leucovorin Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases Recruiting USA 0
NCT05067283 Phase I MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Advanced Solid Tumors (MK-1084-001) Recruiting USA | NZL | ESP | CAN | AUS 10
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05076552 Phase I TACH101 A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer Recruiting USA 0
NCT05084859 Phase I Abiraterone + Prednisone + SM08502 Fluorouracil + Irinotecan + Leucovorin + Panitumumab + SM08502 Docetaxel + SM08502 A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors Active, not recruiting USA | AUS 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05091346 Phase Ib/II E7386 + Pembrolizumab A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Recruiting USA | GBR | FRA | ESP 1
NCT05091528 Phase Ib/II SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers Terminated USA 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated NLD | FRA 0
NCT05099549 Phase Ib/II AFM24 + SNK01 Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers Terminated USA 0
NCT05104567 Phase II Cetuximab + THOR-707 Pembrolizumab + THOR-707 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Active, not recruiting USA | NLD | ITA | FRA | ESP | BEL 3
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05116891 Phase Ib/II Cisplatin + Gemcitabine + Nidanilimab Docetaxel + Nidanilimab Fluorouracil + Leucovorin + Nidanilimab + Oxaliplatin A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Completed FRA | ESP 0
NCT05118841 Phase I ZX-4081 Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors Unknown status USA 0
NCT05121948 Phase I HC-7366 A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Terminated USA 0
NCT05141721 Phase II Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT05167409 Phase II Cetuximab + Evorpacept + Pembrolizumab A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT05176665 Phase Ib/II EMB-01 EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers Recruiting USA 1
NCT05185947 Phase II Nilotinib + Paclitaxel Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer Recruiting USA 0
NCT05201352 Phase Ib/II Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride + XB2001 Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1alpha True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN) Recruiting FRA 0
NCT05201612 Phase II Olaparib + Pembrolizumab Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (PEMBROLA) Recruiting ESP 0
NCT05203172 FDA approved Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 8
NCT05238558 Phase I FMPV-1 + Sargramostim Safety and Immune Response to FMPV-1 Completed GBR 0
NCT05243862 Phase II Atezolizumab + PolyPEPI1018 Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. Active, not recruiting USA 0
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | BEL 4
NCT05259696 Phase Ib/II E-602 E-602 + Pembrolizumab Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) Recruiting USA 0
NCT05263180 Phase I EMB-09 A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. Recruiting AUS 1
NCT05275374 Phase Ib/II BI 882370 + Trametinib BI 882370 XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) Not yet recruiting 0
NCT05277051 Phase I GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP | CAN | AUS 3
NCT05307874 Phase Ib/II Aldesleukin + ICT01 Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) Recruiting FRA 0
NCT05319314 Phase I GCC19CART GCC19CART for Patients With Metastatic Colorectal Cancer (CARAPIA-1) Recruiting USA 0
NCT05330429 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Suspended USA 0
NCT05350501 Phase II EO2040 + Nivolumab EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (CLAUDE) Completed USA 0
NCT05358249 Phase Ib/II JDQ443 + Ribociclib JDQ443 + Trametinib Cetuximab + JDQ443 Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03) Recruiting USA | ITA | FRA | ESP | DEU | BEL 2
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05360680 Phase I CUE-102 A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers Recruiting USA 0
NCT05394103 Phase Ib/II Q901 Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors Recruiting USA 1
NCT05397171 Phase Ib/II AZD8853 A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours Terminated USA | CAN 0
NCT05411133 Phase I ARB202 + Atezolizumab ARB202 Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients Recruiting AUS 1
NCT05427487 Phase I IVX037 Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours Recruiting AUS 0
NCT05446129 Phase I Effi-DEM + Pembrolizumab Effi-DEM + Ezabenlimab A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery Terminated USA 0
NCT05451849 Phase Ib/II Cyclophosphamide + Fludarabine TC-510 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA 0
NCT05453825 Phase II Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors Recruiting USA 0
NCT05462236 Phase II ETC-1907206 ETC-1907206 + Irinotecan ETC-1907206 + Pembrolizumab MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer Recruiting AUS 0
NCT05462613 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Irinotecan + Leucovorin + Regorafenib Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02) Recruiting FRA 0
NCT05464030 Phase I M9140 Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors Recruiting USA | ESP 1
NCT05480306 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe) Recruiting USA | DEU 1
NCT05496595 Phase I DCBY02 DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Terminated USA 0
NCT05500508 Phase Ib/II AMXT1501 + Eflornithine Oral AMXT 1501 Dicaprate in Combination With IV DFMO Recruiting USA | AUS 0
NCT05513742 Phase II CTX-009 A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer Active, not recruiting USA 0
NCT05518032 Phase II Pembrolizumab Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) Not yet recruiting USA 0
NCT05533697 Phase Ib/II mRNA-4359 + Pembrolizumab mRNA-4359 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | AUS 0
NCT05544929 Phase I KFA115 KFA115 + Pembrolizumab A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Recruiting USA | ITA | ESP | DEU | CAN 4
NCT05547321 Phase I OMTX705 + Pembrolizumab OMTX705 Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. Recruiting USA | ESP 0
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05571839 Phase I SGN-BB228 A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors Recruiting USA | GBR | FRA | DEU | CAN 1
NCT05572684 Phase Ib/II NC410 + Pembrolizumab A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Recruiting USA 0
NCT05573035 Phase I LYL845 A Study to Investigate LYL845 in Adults With Solid Tumors Recruiting USA 0
NCT05576896 Phase II Encorafenib + Hydroxychloroquine + Panitumumab Cetuximab + Encorafenib + Hydroxychloroquine Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Recruiting USA 0
NCT05578092 Phase Ib/II Adagrasib + MRTX0902 MRTX0902 A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway Recruiting USA 1
NCT05584709 Phase I STI-6129 Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors Not yet recruiting USA 0
NCT05585034 Phase I Pembrolizumab + XmAb808 Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors Recruiting USA 0
NCT05585320 Phase Ib/II IMM-1-104 A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05592626 Phase Ib/II STAR0602 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | CAN 0
NCT05593328 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation Active, not recruiting USA 0
NCT05597839 Phase Ib/II DF9001 DF9001 + Nivolumab Study of DF9001 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05605522 Phase I 225Ac-FPI-2059 A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours Recruiting USA | AUS 0
NCT05607498 Phase I EMB-07 First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors Recruiting AUS 1
NCT05619172 Phase II Cetuximab + SOT101 A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer Active, not recruiting FRA | ESP | BEL 0
NCT05631574 Phase I BMF-219 Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer Recruiting USA 1
NCT05636215 Phase Ib/II Orismilast A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05646797 Phase I ASP2074 A Study of ASP2074 in Adults With Solid Tumors Active, not recruiting USA 1
NCT05650203 Phase I JS006 + JS009 + Toripalimab-tpzi JS009 A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies Withdrawn 0
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05668585 Phase Ib/II CFT1946 + Trametinib CFT1946 A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors Recruiting USA | FRA | ESP 0
NCT05683418 Phase I TOS-358 A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors Recruiting USA 0
NCT05684965 Phase I XTX301 XTX301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05688280 Phase Ib/II IP-001 Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1) Recruiting USA | GBR | FRA | DEU 1
NCT05691491 Phase Ib/II M1774 + Temozolomide Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness Recruiting USA 0
NCT05694936 Phase II Cetuximab + Panitumumab Cetuximab + Panitumumab + Valproic acid Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer Recruiting AUS 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05718557 Phase I PYX-106 Study of PYX-106 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05719558 Phase I ASP1002 A Study of ASP1002 in Adults for Treatment of Solid Tumors Active, not recruiting USA 0
NCT05731271 Phase Ib/II TST003 A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors Recruiting USA 0
NCT05731947 Phase Ib/II Revumenib Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors Recruiting USA 0
NCT05733000 Phase II CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Recruiting USA 0
NCT05736731 Phase Ib/II A2B530 A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) Recruiting USA 0
NCT05746897 Phase I NM1F + Pembrolizumab NM1F A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05759728 Phase Ib/II CNA3103 A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Recruiting AUS 0
NCT05769959 Phase Ib/II RO7515629 Study of RO7515629 in Participants With HLA-G Positive Solid Tumors Terminated USA 0
NCT05783622 Phase I JANX008 Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies Recruiting USA 0
NCT05785754 Phase I DCSZ11 DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors Recruiting USA | AUS 0
NCT05789069 Phase I HFB200603 HFB200603 + Tislelizumab A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Recruiting USA | ITA | ESP 0
NCT05800964 Phase I AMG 305 Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. Recruiting USA | FRA | ESP | DEU | CAN | AUS 2
NCT05803382 Phase I Capecitabine + ZEN-3694 Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers Recruiting USA 0
NCT05821777 Phase Ib/II LB101 A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors Recruiting USA | FRA 0
NCT05826600 Phase I OMX-0407 A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically Recruiting ESP | BEL 0
NCT05830097 Phase Ib/II CBP-1019 A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05836324 Phase I INCA33890 A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA | ITA | GBR | FRA | ESP 2
NCT05843188 Phase II Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hydroxychloroquine + Irinotecan + Leucovorin Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer Recruiting CAN 0
NCT05848739 Phase I ST316 A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Recruiting USA 0
NCT05862324 Phase Ib/II TAC01-CLDN18.2 TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) Recruiting USA | CAN 0
NCT05892068 Phase II Tucatinib A Study of Tucatinib Given Before Surgery to People With HER2 positive Cancers That Have Spread to the Brain Recruiting USA 0
NCT05900648 Phase II Regorafenib + XmAb20717 Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) Withdrawn 0
NCT05902988 Phase Ib/II VLS-1488 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Recruiting USA 0
NCT05909995 Phase I INCB099280 + Ipilimumab Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors Recruiting USA | CAN 2
NCT05919264 Phase Ib/II FOG-001 FOG-001 in Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05934539 Phase Ib/II ALG.APV-527 ALG.APV-527 First-in-human Study Recruiting USA 0
NCT05944237 Phase Ib/II Atezolizumab + HTL0039732 HTL0039732 HTL0039732 in Participants With Advanced Solid Tumours Recruiting GBR 0
NCT05947474 Phase I ORB-011 ORB-011 In Patients With Advanced Solid Tumors (ORB) Recruiting USA 0
NCT05948865 Phase I CPO301 A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Recruiting USA | CAN 0
NCT05957367 Phase Ib/II DCC-3116 + Ripretinib Cetuximab + DCC-3116 + Encorafenib A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Recruiting USA 0
NCT05969041 Phase I MT-302 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) Recruiting AUS 0
NCT05983133 Phase I SGN-EGFRd2 A Study of SGN-EGFRd2 in Advanced Solid Tumors Recruiting USA 0
NCT05983367 Phase II Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + RGX202 A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer Recruiting FRA | ESP | BEL 0
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT05989724 Phase I SON-DP A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06003998 Phase II Bevacizumab + Fluorouracil + Irinotecan + Oxaliplatin Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab (INTERACT-II) Recruiting NLD 0
NCT06006923 Phase II Pembrolizumab Pembrolizumab + Regorafenib Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer Not yet recruiting USA 0
NCT06014502 Phase I IMGS-001 Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Recruiting USA 0
NCT06024174 Phase Ib/II Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398 A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors Active, not recruiting USA | ITA | FRA | ESP | BEL | AUS 2
NCT06026410 Phase I Cabozantinib + KO-2806 Adagrasib + KO-2806 KO-2806 KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001) Recruiting USA 0
NCT06039384 Phase I Adagrasib + INCB099280 A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Recruiting USA | ITA | GBR | ESP | CAN 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06051695 Phase Ib/II A2B694 A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) Recruiting USA 0
NCT06052852 Phase Ib/II BDC-3042 + Pembrolizumab BDC-3042 Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies Recruiting USA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06084689 Phase II BI 907828 + Ezabenlimab Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) Not yet recruiting FRA 0
NCT06106308 Phase II Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation Recruiting USA 0
NCT06107413 Phase II ABBV-400 + Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab Recruiting USA 4
NCT06108050 Phase I JZP898 + Pembrolizumab JZP898 JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Recruiting USA 0
NCT06129604 Phase II TPST-1495 Pilot Window of Opportunity Trial (POET) Recruiting USA 0
NCT06131398 Phase I AMG 355 + Pembrolizumab AMG 355 A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Recruiting USA | AUS 1
NCT06131840 Phase I SGN-CEACAM5C A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Recruiting USA 0
NCT06149481 Phase Ib/II ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept + Retifanlimab + SX-682 ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept + Retifanlimab Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) Recruiting USA 0
NCT06154291 Phase Ib/II XON7 FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) Recruiting FRA | BEL 0
NCT06171178 Phase I ASP1012 + Pembrolizumab ASP1012 A Study of ASP1012 in Adults With Solid Tumors Recruiting USA 0
NCT06179160 Phase I Cetuximab + INCB161734 + Retifanlimab INCB161734 A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation Recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 0
NCT06194877 Phase I BGB3245 + Panitumumab A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers Recruiting USA 0
NCT06205836 Phase II Cemiplimab Cemiplimab + Fianlimab Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer Not yet recruiting USA 0
NCT06239467 Phase I OKI-219 + Trastuzumab OKI-219 Fulvestrant + OKI-219 First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01) Recruiting USA 0
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06253520 Phase I Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer Recruiting USA 0
NCT06268015 Phase II Balstilimab + Botensilimab + Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Balstilimab + Botensilimab Balstilimab + Bevacizumab + Botensilimab + Fluorouracil + Leucovorin + Oxaliplatin Botensilimab and Balstilimab Optimization in Colorectal Cancer (BBOpCo) Not yet recruiting USA 0
NCT06270082 Phase I IK-595 Study of IK-595 in RAS- or RAF-altered Advanced Tumors Recruiting USA 0
NCT06279130 Phase II Balstilimab Balstilimab + Botensilimab Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) Recruiting NLD 0
NCT06305247 Phase Ib/II IPN01194 A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Recruiting USA | FRA | ESP 0
NCT06328738 Phase I ELVN-002 + Eribulin + Trastuzumab Capecitabine + ELVN-002 + Trastuzumab ELVN-002 + Paclitaxel + Trastuzumab Capecitabine + ELVN-002 + Oxaliplatin + Trastuzumab ELVN-002 + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab ELVN-002 + Trastuzumab ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer Recruiting USA 0
NCT06330064 Phase II Ifinatamab deruxtecan A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXD) In Subjects With Recurrent Or Metastatic Solid Tumors Recruiting USA 0
NCT06331598 Phase II Atezolizumab Atezolizumab + Tiragolumab A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) Recruiting ESP 0
NCT06332274 Phase III Tislelizumab tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA) Not yet recruiting FRA 0
NCT06336902 Phase I Balstilimab + Botensilimab + Vitamin C Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer Not yet recruiting USA 0
NCT06358430 Phase I Cyclophosphamide + Fludarabine Cetuximab + TROP2-CAR/IL15-transduced CBNK cells Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) Not yet recruiting USA 0
NCT06362369 Phase Ib/II 7HP349 + Ipilimumab + Nivolumab A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Not yet recruiting USA 0
NCT06365970 Phase II Dostarlimab-gxly + Niraparib Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers Not yet recruiting USA 0
NCT06369259 Phase II Cetuximab + Defactinib + RO5126766 Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer Not yet recruiting USA 0
NCT06400472 Phase I LY4170156 A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Recruiting USA 0
NCT06410534 Phase II Nivolumab Ipilimumab + Nivolumab A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer Not yet recruiting USA 0